List of DDDs for 3 years revision
The DDDs, which will be reviewed at the March 2022 meeting (3 year revision) are listed below. See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2022.
ATC code | ATC level name (INN/generic name) | DDD | Unit | Adm.route | |
---|---|---|---|---|---|
A04AD11 | nabilone | 3 | mg | O | |
A10BJ06 | semaglutide | 0.11 | mg | P | |
A16AB17 | cerliponase alfa | 21 | mg | P | |
A16AX09 | glycerol phenylbutyrate | 15 | g | O | |
G03XX01 | prasterone | 6.5 | mg | V | |
G04BX15 | pentosan polysulfate sodium | 0.3 | g | O | |
J01AA14 | sarecycline | 0.1 | g | O | |
J01AA15 | omadacycline | 0.3 | g | O | |
J01AA15 | omadacycline | 0.1 | g | P | |
J01DD64 | cefpodoxime and beta-lactamase inhibitor | 0.4 1) | g | O | |
J01MA12 | levofloxacin | 0.24 | g | Inhal.solution | |
J04AA03 | calcium aminosalicylate | 15 | g | O | |
J04AB06 | enviomycin | 1 | g | P | |
J05AB03 | vidarabine | 0.7 | g | P | |
J05AG06 | doravirine | 0.1 | g | O | |
J05AH03 | peramivir | 0.6 | g | P | |
J05AH04 | laninamivir | 40 | mg | Inhal.powder | |
J05AP06 | asunaprevir | 0.2 | g | O | |
J05AP10 | elbasvir | 50 | mg | O | |
J05AP11 | grazoprevir | 0.1 | g | O | |
J05AX25 | baloxavir marboxil | 40 | mg | O | |
J05AX26 | amenamevir | 0.4 | g | O | |
J05AX27 | favipiravir | 1.6 | g | O | |
L02BB05 | apalutamide | 0.24 | g | O | |
L04AB07 | opinercept | 7 | mg | P | |
L04AC12 | brodalumab | 15 | mg | P | |
M03BX03 | pridinol | 6 | mg | O | |
M04AB05 | lesinurad | 0.2 | g | O | |
N02CD01 | erenumab | 2.5 | mg | P | |
N02CD02 | galcanezumab | 4 | mg | P | |
N02CD03 | fremanezumab | 7.5 | mg | P | |
P01CA03 | fexinidazole | 1.44 | g | O | |
V03AE10 | sodium zirconium cyclosilicate | 7.5 | mg | O |
1) Refers to cefpodoxime
Last updated: 2021-12-08